NCT05061368View on ClinicalTrials.gov

Oral Sildenafil for Exercise Capacity, Dyspnea and Cardiopulmonary Function in COPD

PHASE2RecruitingINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

Sildenafil Citrate

Phosphodiesterase Type 5 inhibitor. Known to potentiate nitric oxide mediated vasodilation.

OTHER

Placebo

Placebo

Trial Locations (1)

T6G2R3

RECRUITING

Clinical Physiology Laboratory, Edmonton

All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

lead

University of Alberta

OTHER